Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/HCV-coinfected patients with advanced liver disease
M Mandorfer, P Schwabl, S Steiner, D Chromy, T Bucsics, AF Stättermayer, MC Aichelburg, K Grabmeier-Pfistershammer, M Trauner, T Reiberger, M Peck-Radosavljevic · Zeitschrift für Gastroenterologie · 2016 · Heft 05
Bibliografische Angaben
Zusammenfassung
Aim: We aimed to investigate the safety and efficacy of interferon (IFN)- and ribavirin (RBV)-free therapy with of sofosbuvir plus daclatasvir (SOF/DCV) in HIV/HCV-coinfected patients (HIV/HCV), who have an urgent need for effective antiviral therapy. We also assessed its impact on liver stiffness. Methods: Thirty-one thoroughly documented HIV/HCV with advanced liver disease (advanced liver fibrosis and/or portal hypertension) who were treated with SOF/DCV were retrospectively studied. The following treatment durations were applied: HCV-genotype (HCV-GT)1/4 without cirrhosis: 12 weeks; HCV-GT1/4 with cirrhosis:…
